Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date † | September 16, 2004 | ||||||||
Last Updated Date | November 4, 2005 | ||||||||
Start Date † | September 1997 | ||||||||
Current Primary Outcome Measures † | |||||||||
Original Primary Outcome Measures † | |||||||||
Change History | Complete list of historical versions of study NCT00091728 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures † | |||||||||
Original Secondary Outcome Measures † | |||||||||
Descriptive Information | |||||||||
Brief Title † | Hormonal Contraception and Risk of Chlamydia and Gonorrhea | ||||||||
Official Title † | Hormonal Contraception, Cervical Ectopy, and STDs | ||||||||
Brief Summary | There are biological reasons to suspect that hormones may affect the risk of a woman becoming infected with a sexually transmitted disease. The evidence on this issue to date is mixed and previous studies have methodologic flaws making it difficult to draw conclusions about the results. This study compares the risk of developing either Chlamydial or Gonorrheal infection among three groups of women: those using combined oral contraceptives (birth control pills); those using the injectable hormone (brand name Depo Provera); and those women using non-hormonal contraceptive methods. |
||||||||
Detailed Description | The study was designed to examine the relationship between hormonal contraceptive use and possible increased risk of Chlamydial and Gonococcal sexually transmitted infections, and to determine if any increased risk appeared to be mediated by the extent of cervical ectopy. Eight hundred and nineteen women, ages 15 to 45 years, were recruited from an inner city clinic and from a nearby suburban clinic. The women were classified into three groups based on type of contraceptive used. One group used oral contraceptives; the second used injectable depo-medroxyprogesterone acetate (DMPA); and the third group used non-hormonal contraceptive methods. Women from each group were followed at 3, 6, and 12 months after enrollment to determine if a new infection with Chlamydia or Gonorrhea had occurred and to evaluate the extent of cervical ectopy present. |
||||||||
Study Phase | Phase IV | ||||||||
Study Type † | Observational | ||||||||
Study Design † | Natural History, Longitudinal, Defined Population, Prospective Study | ||||||||
Condition † |
|
||||||||
Intervention † |
|
||||||||
Study Arms / Comparison Groups | |||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status † | Terminated | ||||||||
Enrollment † | 1200 | ||||||||
Completion Date | August 2001 | ||||||||
Primary Completion Date | |||||||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Female | ||||||||
Ages | 15 Years to 45 Years | ||||||||
Accepts Healthy Volunteers | Yes | ||||||||
Contacts †† | |||||||||
Location Countries † | |||||||||
Expanded Access Status | |||||||||
Administrative Information | |||||||||
NCT ID † | NCT00091728 | ||||||||
Responsible Party | |||||||||
Secondary IDs †† | |||||||||
Study Sponsor † | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | ||||||||
Collaborators †† | |||||||||
Investigators † |
|
||||||||
Information Provided By | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | ||||||||
Verification Date | September 2004 | ||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |